The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessAbstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality. Among patients who undergo computed tomography (CT) within three hours after the onset of intracerebral hemorrhage, one third have an increase in the volume of the hematoma related to subsequent bleeding. We sought to determine whether recombinant activated factor VII (rFVIIa) can reduce hematoma growth after intracerebral hemorrhage. METHODS: We randomly assigned 399 patients with intracerebral hemorrhage diagnosed by CT within three hours after onset to receive placebo (96 patients) or 40 microg of rFVIIa per kilogram of body weight (108 patients), 80 microg per kilogram (92 patients), or 160 microg per kilogram (103 patients) within one hour after the baseline scan. The primary outcome measure was the percent change in the volume of the intracerebral hemorrhage at 24 hours. Clinical outcomes were assessed at 90 days. RESULTS: Hematoma volume increased more in the placebo group than in the rFVIIa groups. The mean increase was 29 percent in the placebo group, as compared with 16 percent, 14 percent, and 11 percent in the groups given 40 microg, 80 microg, and 160 microg of rFVIIa per kilogram, respectively (P=0.01 for the comparison of the three rFVIIa groups with the placebo group). Growth in the volume of intracerebral hemorrhage was reduced by 3.3 ml, 4.5 ml, and 5.8 ml in the three treatment groups, as compared with that in the placebo group (P=0.01). Sixty-nine percent of placebo-treated patients died or were severely disabled (as defined by a modified Rankin Scale score of 4 to 6), as compared with 55 percent, 49 percent, and 54 percent of the patients who were given 40, 80, and 160 microg of rFVIIa, respectively (P=0.004 for the comparison of the three rFVIIa groups with the placebo group). Mortality at 90 days was 29 percent for patients who received placebo, as compared with 18 percent in the three rFVIIa groups combined (P=0.02). Serious thromboembolic adverse events, mainly myocardial or cerebral infarction, occurred in 7 percent of rFVIIa-treated patients, as compared with 2 percent of those given placebo (P=0.12). CONCLUSIONS: Treatment with rFVIIa within four hours after the onset of intracerebral hemorrhage limits the growth of the hematoma, reduces mortality, and improves functional outcomes at 90 days, despite a small increase in the frequency of thromboembolic adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationBroderick, J. P., Adams, H. P., Barsan, W., Feinberg, W., Feldmann, E., Grotta, J., Kase, C., Krieger, D., Mayberg, M., Tilley, B., et al. (1999) · Stroke · doi:10.1161/01.str.30.4.905 · Cited by 830
Self-citationEnlargement of Spontaneous Intracerebral Hemorrhage: Incidence and Time Course
Kazui, S., Naritomi, H., Yamamoto, H., Sawada, T., & Yamaguchi, T. (1996) · Stroke · doi:10.1161/01.str.27.10.1783 · Cited by 572
Platelet activity of high‐dose factor VIIa is independent of tissue factor
Monroe, D. M., Hoffman, M., Oliver, J. A., & Roberts, H. R. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4463256.x · Cited by 534
Hematoma enlargement in spontaneous intracerebral hemorrhage
Fujii, Y., Tanaka, R., Takeuchi, S., Koike, T., Minakawa, T., & Sasaki, O. (1994) · Journal of Neurosurgery · doi:10.3171/jns.1994.80.1.0051 · Cited by 350
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
Lindley, C. M., Sawyer, W. T., Macik, B. G., Lusher, J., Harrison, J. F., Baird-Cox, K., Birch, K., Glazer, S., & Roberts, H. R. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.80 · Cited by 255
Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2005) · Stroke · doi:10.1161/01.str.0000149628.80251.b8 · Cited by 234
Self-citationUltra-Early Hemostatic Therapy for Intracerebral Hemorrhage
Mayer, S. A. (2003) · Stroke · doi:10.1161/01.str.0000046458.67968.e4 · Cited by 215
Self-citationPrimary Intracerebral Haemorrhage in the Oxfordshire Community Stroke Project
Counsell, C. E., Boonyakarnkul, S., Dennis, M. S., Sandercock, P. A., Bamford, J., Burn, J., & Warlow, C. P. (1995) · Cerebrovascular Diseases · doi:10.1159/000107814 · Cited by 155
The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX
He, S., Blombäck, M., Ekman, G. J., et al. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00242.x · Cited by 140
Indications for surgical treatment of putaminal hemorrhage
Fujitsu, K., Muramoto, M., Ikeda, Y., Inada, Y., Kim, I., & Kuwabara, T. (1990) · Journal of neurosurgery · doi:10.3171/jns.1990.73.4.0518 · Cited by 118
The Emerging Role of Recombinant-Activated Factor VII in Neurocritical Care
Fewel, M. E., & Park, P. (2004) · Neurocritical Care · doi:10.1385/ncc:1:1:19 · Cited by 33
Cited by
Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
Donnan, G. A., Fisher, M., Macleod, M., & Davis, S. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60694-7 · Cited by 2,218
Self-citationPharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Greenberg, S. M., Ziai, W. C., Cordonnier, C., Dowlatshahi, D., Francis, B., Goldstein, J. N., Hemphill, J. C., Johnson, R., Keigher, K. M., Mack, W. J., et al. (2022) · Stroke · doi:10.1161/str.0000000000000407 · Cited by 1,639
Qureshi, A. I., Mendelow, A. D., & Hanley, D. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60371-8 · Cited by 1,526
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-02-24
- Volume
- 352
- Issue
- 8
- Pages
- 777-785
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238103798
- Cited by
- 1,167
- References
- 18
- FWCI
- 99.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.